Results 51 to 60 of about 2,317 (166)

Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials

open access: yesJournal of International Medical Research, 2020
Purpose Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol compared with other second-generation β blockers for hypertensive patients.
Jun-Ying Liu   +6 more
doaj   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

open access: yesEuropean Journal of Heart Failure, Volume 27, Issue 11, Page 2198-2210, November 2025.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde   +24 more
wiley   +1 more source

Effect of nebivolol on liver regeneration in an experimental 70% partial hepatectomy model

open access: yesAsian Journal of Surgery, 2017
Background: Factors affecting liver regeneration are still relevant. The purpose of this study is to investigate the effect of nebivolol treatment on liver regeneration in rats in which 70% partial hepatectomy was performed.
Fatih Sumer   +6 more
doaj   +1 more source

Integrating Nanotechnology With 3D Printing for Drug Delivery: Bone Regeneration and Beyond

open access: yesNano Select, Volume 6, Issue 11, November 2025.
What happens when nanotechnology meets 3D printing? This review explores how their fusion transforms drug delivery and bone regeneration, creating smarter, more adaptable therapies. From nanomaterials to futuristic fabrication methods, the article maps innovations that could redefine personalized medicine and hints at the challenges researchers must ...
Felipe Sousa Siqueira   +2 more
wiley   +1 more source

A review of the safety and efficacy of nebivolol in the mildly hypertensive patient

open access: yesVascular Health and Risk Management, 2008
John CockcroftWales Heart Research Institute, University Hospital Heath Park, Cardiff, UKAbstract: Nebivolol is a third generation beta-blocker, which can be distinguished from other beta-blockers by its hemodynamic profile.
John Cockcroft
doaj  

Nebivolol Attenuates Neutrophil Lymphocyte Ratio: A Marker of Subclinical Inflammation in Hypertensive Patients

open access: yesInternational Journal of Hypertension, 2017
Background. High value of neutrophil lymphocyte ratio (NLR) is a strong independent predictor and biomarker of ongoing vascular inflammation in various cardiovascular disorders. Objective.
Mazhar Hussain   +4 more
doaj   +1 more source

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE

open access: yesРациональная фармакотерапия в кардиологии, 2015
Review is devoted to the role of modern beta-blocker nebivolol in the treatment of stable ischemic heart disease (IHD). The mode of nebivolol anti-ischemic activity is considered, as well as its use particularities in IHD patients with different ...
V. P. Lupanov
doaj   +1 more source

Extemporaneous combination therapy with nebivolol/zofenopril in hypertensive patients: usage in Italy [PDF]

open access: hybrid, 2022
Massimo Volpe   +4 more
openalex   +1 more source

Amiodarone‐Induced Pulmonary Toxicity in an Elderly Patient: A Case Report

open access: yesClinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Amiodarone, a widely utilized and effective class III antiarrhythmic agent, carries a significant risk of severe organ toxicities, notably including the pulmonary system. This report details a case of an 82‐year‐old female who developed amiodarone‐induced pulmonary toxicity (APT) following 2 years of standard 200 mg daily maintenance therapy ...
Bal Krishna Subedi   +4 more
wiley   +1 more source

The Effect of Nebivolol on Acute Renal Injury Developed After Myocardial Ischemia: A Preclinical Study

open access: yesHaseki Tıp Bülteni, 2018
Aim:During reperfusion of myocardial ischemia, damage can also be seen in the kidneys. Although many studies have been conducted on the underlying mechanisms, the basic mechanism of this interaction is still unknown.
Güldem Mercanoğlu   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy